Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402993 | 0.87 | DDB1 (0.51) | DDB1CRBNHTR4OPRL1OPRM1 | |
| SCHEMBL24269178 | 0.87 | DDB1 (0.51) | DDB1CRBNHTR4OPRL1OPRM1 | |
| SCHEMBL28649449 | 0.85 | DDB1 (0.53) | DDB1CRBN | |
| SCHEMBL27178155 | 0.85 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL29347429 | 0.82 | DDB1 (0.48) | DDB1CRBNHTR4OPRL1OPRM1 | |
| SCHEMBL22525513 | 0.81 | DDB1 (0.49) | DDB1CRBN | |
| SCHEMBL29347124 | 0.81 | DDB1 (0.47) | DDB1CRBNHTR4OPRL1OPRM1 | |
| SCHEMBL24269308 | 0.78 | DDB1 (0.51) | DDB1CRBNOPRL1OPRM1OPRK1 | |
| SCHEMBL25036211 | 0.78 | DDB1 (0.53) | DDB1CRBNHTR4OPRL1OPRM1 | |
| SCHEMBL24269143 | 0.78 | CRBN (0.55) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | DDB1 33/4885CRBN 91/4885HTR4 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.